多西他赛联合顺铂治疗蒽环类耐药晚期乳腺癌疗效分析

Docetaxel combined with cisplatin in treatment of anthracycline-resistant advanced breast cancer

摘要: 目的: 观察多西他赛联合顺铂治疗蒽环类耐药晚期乳腺癌疗效及安全性。方法: 多西他赛75mg/m²,静脉滴注,第1天;顺铂25mg/m²,静脉滴注,第1～3天,21天为1周期,2周期后评价疗效。结果: 35例均可评价疗效,完全缓解(CR)5例,部分缓解(PR)19例,稳定(SD)6例,进展(PD)5例,总有效率(CR+PR)68.6%。毒副反应为恶心、呕吐、脱发和骨髓抑制。结论: 多西他赛联合顺铂治疗蒽环类耐药晚期乳腺癌疗效较好,毒副反应可耐受,可作为该类患者的治疗选择。

Abstract: Objective: To evaluate the efficacy and safety of Docetaxel combined with cisplatin in treatment of anthracycline-resistant advanced breast cancer.Methods: Docetaxel 75 mg/m² intravenous drip was given at d₁ and cisplatin 25 mg/m² was given intravenous drip at d_1-3.One cycle consisted of 3 weeks.The clinical response was assessed after two cycles.Results: Of the 35 patients,5 achieved complete remission,19 partial remission,6 SD and 5 PD,with a response rate of 68.6%.The main side effects were vomiting,alopecia and neutropenia.Conclusions: Docetaxe and displatin combination is effective on anthracycine-resistant advanced breast cancer with acceptable toxicity.It provides an alternative for patients with advanced breast cancer.